4C Controls (OTC:FOUR)

,

Who gets them first SEC or IRS?

As much as Citron has been attempting to avoid OTC Stocks, occasionally one comes along that is so absurd that we can not help commenting on it. Enter 4C Controls. This $400 million company has spun a tale that leaves us with the daunting question:

What is worse about this company: “The Tale or the Truth” ?

Read more

Seeking Healthy Returns in Amedisys? (NASDAQ:AMED)

,

Better get a Second Opinion….

Citron Research was first drawn to research Arthrocare because one division was running margins that wildly outperformed all their competitors.  After working countless hours with private investigators and reviewing hundreds of documents, we were able to draw a line to what we believe explained the extreme outperformance:  fraud on the insurance reimbursement system.  Well… here we go again.

(Citron notes that within the last month alone, two companies — ARTC and BWTR both formerly reported by Citron — were forced to restate previous earnings, and their shares were cut in half.)

Read more

Citron updates American Superconductor (NASDAQ:AMSC)

,

What is a Power Module Company Really Worth?

For the past two months, Citron has maintained its opinion that the business of selling power modules to the wind industry does not classify a company as a “wind play”, but more accurately an industrial commodity.  Meanwhile, sell side analysts have ignored all warnings, as well as large insider selling and questionable SEC confidentiality requests cloaking the company’s single largest piece of projected business.  Citron will now put forth the one piece of evidence that shareholders cannot afford to ignore.  As for the analysts, ignoring things is standard practice.

Read more